Caris Life Sciences (CAI) Change in Receivables (2024 - 2026)

Caris Life Sciences' Change in Receivables history runs 3 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 173.26% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $29.8 million, down 11.91% from the prior year.
• Change in Receivables was -$21.6 million for Q1 2026 at Caris Life Sciences, down from $91.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $91.0 million in Q4 2025 to a low of -$29.1 million in Q2 2025.
• Historically, Change in Receivables has averaged $3.6 million across 3 years, with a median of -$7.9 million in 2025.
• Biggest YoY gain for Change in Receivables was 383.97% in 2025; the steepest drop was 1176.62% in 2025.
• A 3-year view of Change in Receivables shows it stood at $18.8 million in 2024, then jumped by 383.97% to $91.0 million in 2025, then plunged by 123.76% to -$21.6 million in 2026.
• The last three Change in Receivables figures came in at -$21.6 million (Q1 2026), $91.0 million (Q4 2025), and -$24.2 million (Q3 2025), per Business Quant data.